Quality of vitamin K antagonist treatment during the last year of life

Figures

• 

  Figure 1. Flowchart of the selection of our study cohort. A severe medical condition is defined as “a diagnosis that carries an increased risk of mortality, hospitalization and emergency room visits.” 34 DOAC, direct oral anticoagulant; INR, international normalized ratio; VKA, vitamin K antagonists. Created in BioRender. Kruip, M. (2025), https://BioRender.com/a20d177.

• 

  Figure 2. Anticoagulation control in the last year of life. Bar charts with 95% confidence intervals of the mean time below therapeutic range, time in therapeutic range, and time above therapeutic range, along with the mean variability of INR measurements expressed as the variance growth rate, calculated across four distinct intervals leading up to death: 0–12 months (A), 0–9 months (B), 0–6 months (C), and 0–3 months (D) before death.

• 

  Figure 3. Anticoagulation control in two subcohorts of VKA users stratified based on survival time since severe medical condition diagnosis. Anticoagulation control is expressed as the percentage of time spent within the therapeutic range (green line), above the therapeutic range (red line), and below the therapeutic range (blue line). The dotted lines represent the 95% confidence intervals for each metric. The variance growth rate is depicted with gray bars, accompanied by 95% confidence intervals.

• 

  Figure 4. Anticoagulation quality in two subcohorts of VKA users stratified based on survival time since severe medical condition diagnosis and type of severe medical condition. Anticoagulation quality is expressed as the percentage of time spent within the therapeutic range (green line), above the therapeutic range (red line), and below the therapeutic range (blue line). The dotted lines represent the 95% confidence intervals for each metric. The variance growth rate is depicted with gray bars, accompanied by 95% confidence intervals. Anticoagulation quality is displayed in patients with cancer surviving ≥365 days (A) and 180–364 days (B) following cancer diagnosis and in patients with non‐cancer severe medical conditions surviving ≥365 days (C) and 180–364 days (D) following severe medical condition diagnosis.